Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
DYNABAC (dirithromycin) is an oral macrolide antibiotic approved in 1995 for bacterial infections. It is a delayed-release tablet formulation that provides broad-spectrum coverage against respiratory and skin pathogens. The drug works by inhibiting bacterial protein synthesis via ribosomal binding.
As LOE approaches, the brand team is likely in defensive/optimization mode with reduced commercial investments and focus on patient retention and cost management.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Semi-replicate Crossover Bioequivalence Study of Dirithromycin of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions
Semi-replicate Crossover Bioequivalence Study of Dirithromycin in Healthy Subjects Under Fed Conditions
Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed Condition
Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition
Worked on DYNABAC at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on DYNABAC offers limited growth opportunities due to its LOE-approaching status and minimal linked job openings (0 identified). Career development here is best suited for professionals seeking defensive market management experience or transition roles preparing for portfolio maturation.